今日盘中，专注于肿瘤患者基因检测的燃石医学（股票代码：BNR）股价出现大幅上涨，涨幅高达24.58%，引发市场广泛关注。
燃石医学是一家专注于癌症诊断的公司，主要提供覆盖靶向治疗、免疫治疗等场景的多基因平行检测服务，旨在助力临床用药决策。该公司的业务涵盖中心实验室、院内服务和医药研发服务三个主要领域。
值得注意的是，燃石医学与迪哲医药（股票代码：688192）合作开发的EGFR exon20ins伴随诊断试剂盒于2024年10月获得批准，成为中国首个基于NGS技术的肺癌伴随诊断产品。这一重要里程碑可能是推动公司股价大幅上涨的主要因素之一，反映了投资者对公司在癌症诊断领域的创新能力和市场前景的积极评价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.